Patrick Verschueren

6.8k total citations
178 papers, 2.5k citations indexed

About

Patrick Verschueren is a scholar working on Rheumatology, Hematology and Genetics. According to data from OpenAlex, Patrick Verschueren has authored 178 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 139 papers in Rheumatology, 43 papers in Hematology and 35 papers in Genetics. Recurrent topics in Patrick Verschueren's work include Rheumatoid Arthritis Research and Therapies (124 papers), Systemic Lupus Erythematosus Research (56 papers) and Autoimmune and Inflammatory Disorders Research (37 papers). Patrick Verschueren is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (124 papers), Systemic Lupus Erythematosus Research (56 papers) and Autoimmune and Inflammatory Disorders Research (37 papers). Patrick Verschueren collaborates with scholars based in Belgium, Netherlands and United Kingdom. Patrick Verschueren's co-authors include René Westhovens, Xavier Bossuyt, Diederik De Cock, Frank P. Luyten, Kristien Van der Elst, Greet Esselens, Daniël Blockmans, Johan Joly, Godelieve Mariën and Sofia Pazmiño and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Patrick Verschueren

162 papers receiving 2.5k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Patrick Verschueren	1.7k	480	434	383	337	178	2.5k
Rachel Knevel	2.0k 1.2×	440 0.9×	452 1.0×	353 0.9×	471 1.4×	71	2.6k
Saedís Saevarsdóttir	1.7k 1.0×	471 1.0×	855 2.0×	306 0.8×	314 0.9×	103	2.7k
Camilla Bengtsson	2.4k 1.4×	409 0.9×	592 1.4×	346 0.9×	621 1.8×	52	3.3k
Philippe Gaudin	2.3k 1.4×	829 1.7×	644 1.5×	408 1.1×	210 0.6×	148	3.4k
P. T. Dawes	1.9k 1.1×	560 1.2×	533 1.2×	329 0.9×	290 0.9×	100	3.0k
Gilles Boire	1.9k 1.1×	420 0.9×	667 1.5×	742 1.9×	554 1.6×	157	3.3k
Jacques Tébib	1.3k 0.8×	386 0.8×	669 1.5×	208 0.5×	247 0.7×	91	2.3k
Chris Deighton	1.5k 0.9×	419 0.9×	514 1.2×	251 0.7×	255 0.8×	73	2.4k
Mohammed Tikly	1.5k 0.9×	396 0.8×	655 1.5×	614 1.6×	209 0.6×	110	2.5k
Michel De Bandt	1.3k 0.8×	506 1.1×	693 1.6×	302 0.8×	162 0.5×	81	2.7k

Countries citing papers authored by Patrick Verschueren

Since Specialization

Citations

This map shows the geographic impact of Patrick Verschueren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Verschueren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Verschueren more than expected).

Fields of papers citing papers by Patrick Verschueren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Verschueren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Verschueren. The network helps show where Patrick Verschueren may publish in the future.

Co-authorship network of co-authors of Patrick Verschueren

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Verschueren. A scholar is included among the top collaborators of Patrick Verschueren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Verschueren. Patrick Verschueren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bertrand, Delphine, et al.. (2024). Treat-to-target fixed dose rituximab retreatment versus fixed interval retreatment with disease activity-guided rituximab dose optimisation for patients with rheumatoid arthritis: study protocol for a multicentre randomised controlled superiority trial focusing on long-term disease impact (RITUXERA). Trials. 25(1). 681–681. 1 indexed citations

Buch, Maya H, Daniel Aletaha, Bernard Combe, et al.. (2024). Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study. RMD Open. 10(4). e004476–e004476. 1 indexed citations

Bertrand, Delphine, et al.. (2024). A mobile app to support self-management and remotely monitor disease impact in rheumatoid arthritis: the randomized controlled AEGORA trial. Lara D. Veeken. 64(5). 2505–2514. 1 indexed citations

Verschueren, Patrick, Maarten Boers, Paul Emery, et al.. (2023). Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time?. Annals of the Rheumatic Diseases. 83(1). 65–71. 3 indexed citations

Quartier, Pierre, Lien De Somer, Bernard Lauwerys, et al.. (2023). Patterns and determinants of response to novel therapies in juvenile and adult-onset polyarthritis. Lara D. Veeken. 63(3). 594–607. 4 indexed citations

Kalkanis, Alexandros, Heleen Cypers, Barbara Neerinckx, et al.. (2023). Ultrasonographic Presentation and Anatomic Distribution of Lung Involvement in Patients with Rheumatoid Arthritis. Diagnostics. 13(18). 2986–2986. 6 indexed citations

Pazmiño, Sofia, Anikó Lovik, Annelies Boonen, et al.. (2022). New indicator for discordance between patient-reported and traditional disease activity outcomes in patients with early rheumatoid arthritis. Lara D. Veeken. 62(1). 108–115. 8 indexed citations

Bergstra, Sytske Anne, Alexandre Sepriano, Andreas Kerschbaumer, et al.. (2022). Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases. 82(1). 81–94. 56 indexed citations

Kerschbaumer, Andreas, Alexandre Sepriano, Sytske Anne Bergstra, et al.. (2022). Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases. 82(1). 95–106. 90 indexed citations

10.

Palmowski, Andriko, Frank Buttgereit, Patrick Verschueren, et al.. (2022). Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 81(7). 937–943. 15 indexed citations

11.

Sepriano, Alexandre, Andreas Kerschbaumer, Sytske Anne Bergstra, et al.. (2022). Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases. 82(1). 107–118. 80 indexed citations

12.

Verdonck, Tim, Sofia Pazmiño, Veerle Stouten, et al.. (2021). POS1434 WHICH PROGNOSTIC FACTORS MIGHT PREDICT THE NEED FOR TREATMENT ADAPTATION IN EARLY RHEUMATOID ARTHRITIS? A COMPARISON OF MACHINE LEARNING, SURVIVAL ANALYSIS AND REGRESSION METHODS. Annals of the Rheumatic Diseases. 80. 1001–1002. 1 indexed citations

13.

Schaardenburg, Dirkjan van, Maarten Boers, Diederik De Cock, et al.. (2018). Prevalence and validity of ACR/EULAR remission in four European early rheumatoid arthritis cohorts.. Pure Amsterdam UMC. 36(3). 362–370. 4 indexed citations

14.

Wauters, Lucas, Steven Joniau, Patrick Verschueren, et al.. (2015). Anti-TNF treatment and renal cell carcinoma in patients with inflammatory bowel disease, rheumatoid arthritis and spondyloarthropathy: trigger or cure?. 9. 1 indexed citations

15.

Cock, Diederik De, René Westhovens, Johan Joly, et al.. (2014). Comparison of MTX Therapy with or without A Moderate Dose Glucocorticoid Bridging Scheme in Early Rheumatoid Arthritis Patients Lacking Classical Poor Prognostic Markers: Week 16 Results from the Randomized Multicenter Carera Trial. Annals of the Rheumatic Diseases. 73. 220. 2 indexed citations

16.

Bossuyt, Xavier, et al.. (2013). The phenotype and genotype of rheumatoid arthritis in the Democratic Republic of Congo. Clinical Rheumatology. 32. 1 indexed citations

17.

Durnez, Anne, Geert Vanderschueren, L. Lateur, René Westhovens, & Patrick Verschueren. (2010). Effectiveness of initial treatment allocation based on expert opinion for prevention of rapid radiological progression in a daily practice early RA cohort: room for improvement ?. Annals of the Rheumatic Diseases. 69. 675. 3 indexed citations

18.

Verschueren, Patrick, Greet Esselens, & René Westhovens. (2008). Predictors of remission, normalized function and changes in the working situation of patients with early RA. Annals of the Rheumatic Diseases. 67. 601. 1 indexed citations

19.

Verschueren, Patrick, et al.. (2008). Activation of bone morphogenetic protein signalling in rheumatoid arthritis. Annals of the Rheumatic Diseases. 67. 1 indexed citations

20.

Verschueren, Patrick, H. M. Markusse, Tom Smeets, et al.. (1999). Reduced cellularity and expression of adhesion molecules and cytokines after treatment with soluble human recombinant TNF receptor (P75) in RA patients. Arthritis & Rheumatism. 42(9). 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact